University of Minnesota. Driven to Discover.
The oropharyngeal cancer rate increased 2.8% per year in men and 0.6% in women.
Former smokers had triple the risk, while those with more than 6 sex partners had a sixfold risk.
The results confirm, however, that the vaccine is most effective when given at younger ages.
HPV-related head and neck cancers are dramatically higher in men than in women.
The study involved almost 5,000 women in a country with high vaccine uptake.
Researchers report a 97.4% efficacy for the 9-strain HPV vaccine.
Though coverage still isn't optimal, for the first time rates topped 60%, with the boys' level gaining ground on the girls'.
ACIP spent several months reviewing clinical trial data that showed two doses in younger adolescents prompted an immune response similar to or higher than in young adults.
According to a new estimate, nearly 80% of HPV-related cancer was due to infection, much of it preventable with current vaccines.
HPV vaccine uptake, though up slightly, was just 60% in girls and 42% in boys.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.